<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004242</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067487</org_study_id>
    <secondary_id>AECM-1199904138</secondary_id>
    <secondary_id>NCI-T99-0023</secondary_id>
    <secondary_id>NYU-9944</secondary_id>
    <nct_id>NCT00004242</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>Phase I Study of Oxaliplatin in Combination With 5-Fluorouracil and Gemcitabine in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combination chemotherapy in treating patients who&#xD;
      have metastatic or unresectable solid tumors. Drugs used in chemotherapy use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Combining more than one drug&#xD;
      may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose, recommended phase II dose, and associated toxic&#xD;
      effects of the triple combination of continuous infusion fluorouracil, weekly gemcitabine,&#xD;
      and oxaliplatin in patients with metastatic or unresectable solid tumors.&#xD;
&#xD;
      II. Define sequence dependent toxic effects, if any, and establish pharmacokinetic and&#xD;
      pharmacodynamic relationships in context of this triple combination chemotherapy in this&#xD;
      patient population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of oxaliplatin and gemcitabine.&#xD;
&#xD;
      For course 1, and then course 3 and beyond, patients receive oxaliplatin IV over 2 hours on&#xD;
      day 1, followed by gemcitabine IV over 30 minutes on days 1 and 8, and then fluorouracil IV&#xD;
      continuously on days 1-14. For course 2, patients receive treatment in the same manner as in&#xD;
      course 1, except gemcitabine is given initially, followed by oxaliplatin, and then&#xD;
      fluorouracil. Treatment continues every 21 days in the absence of unacceptable toxicity or&#xD;
      disease progression.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of oxaliplatin and gemcitabine until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity. The recommended phase II dose (RPTD)&#xD;
      is defined as the dose preceding MTD.&#xD;
&#xD;
      Once RPTD is defined, the cohort is expanded to an additional 13 patients. These patients&#xD;
      receive a fixed dose of oxaliplatin, gemcitabine, and fluorouracil as determined by the phase&#xD;
      I dose escalation portion of this study.&#xD;
&#xD;
      Patients are followed for disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or clinically confirmed metastatic or unresectable solid tumor for&#xD;
             which no standard curative or palliative therapy exists or is no longer&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Proven Gilbert's syndrome (UGT1A1 promoter mutation or clinical&#xD;
&#xD;
          -  documentation of stress bilirubin levels) allowed&#xD;
&#xD;
          -  AST/ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No unexplained respiratory problems (e.g., nonproductive cough, dyspnea,&#xD;
&#xD;
          -  rales, pulmonary infiltrates, hypoxia, or tachypnea)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinical evidence of neuropathy&#xD;
&#xD;
          -  No prior allergy to platinum compounds&#xD;
&#xD;
          -  No prior allergy to antiemetics appropriate for administration in&#xD;
&#xD;
          -  conjunction with protocol directed chemotherapy&#xD;
&#xD;
          -  No other concurrent uncontrolled illness (e.g., active infection)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and&#xD;
&#xD;
          -  platinum) and recovered&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for cancer&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent antiretroviral agents (HAART)&#xD;
&#xD;
          -  No other concurrent investigational agents or commercial therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard S. Hochster, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Basu S, Goel S, Hochster H, et al.: Phase I and pharmacokinetic (PK) study of oxaliplatin (Ox) with gemcitabine (Gem) and continuous intravenous (CIV) infusion 5-fluorouracil (FU) in patients with advanced solid malignancies. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2132, 2002.</citation>
  </results_reference>
  <verification_date>July 2002</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

